2024年
- Yamada S, Uchida Y, Kouyama JI, Naiki K, Yamaguchi H, Nakayama N, Imai Y, Mizuno S, Yamada T, Mochida S. Comprehensive genome analysis of hepatitis B virus using nanopore sequencing technology in patients with previously resolved infection and spontaneous reactivation without drug exposure. Clin J Gastroenterol. 2025 Feb;18(1):145-153. doi: 10.1007/s12328-024-02078-8. Epub 2024 Dec 3. PubMed PMID: 39625631.
- Soma N, Uchida Y, Kouyama JI, Naiki K, Usui N, Sato A, Yamada S, Tsuji S, Ando S, Sugawara K, Nakao M, Nakayama N, Imai Y, Tomiya T, Mizuno S, Mochida S. Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis. J Gastroenterol. 2025 Jan;60(1):96-106. doi: 10.1007/s00535-024-02160-5. Epub 2024 Oct 16. PubMed PMID: 39412575.
- Yamada S, Uchida Y, Kouyama JI, Naiki K, Tsuji S, Uemura H, Sugawara K, Nakayama N, Imai Y, Tomiya T, Mizuno S, Mochida S. Switching from combination therapy with entecavir hydrate plus tenofovir alafenamide fumarate to tenofovir alafenamide fumarate monotherapy in patients with chronic hepatitis B based on nucleotide sequences of hepatitis B virus pregenome RNA. Hepatol Res. 2024 Oct;54(10):877-887. doi: 10.1111/hepr.14036. Epub 2024 Mar 22. PubMed PMID: 38517681.
2023年
- Uchida Y, Imai Y, Tsuji S, Uemura H, Kouyama JI, Naiki K, Ando S, Sugawara K, Nakao M, Nakayama N, Mizuno S, Tomiya T, Mochida S. Significance of portal venous blood flow as a factor to determine liver function in patients with decompensated cirrhosis due to hepatitis C virus infection following achievement of sustained viral response by sofosbuvir plus velpatasvir. Hepatol Res. 2023 Sep;53(9):815-828. doi: 10.1111/hepr.13926. Epub 2023 Jun 15. PubMed PMID: 37243512.
2022年
- Uchida Y, Nakao M, Yamada S, Tsuji S, Uemura H, Kouyama JI, Naiki K, Sugawara K, Nakayama N, Imai Y, Tomiya T, Mochida S. Superiority of tenofovir alafenamide fumarate over entecavir for serum HBsAg level reduction in patients with chronic HBV infection: A 144-week outcome study after switching of the nucleos(t)ide analog. PLoS One. 2022 Feb 18;17(2):e0262764. doi: 10.1371/journal.pone.0262764. PubMed PMID: 35180213; PMCID: PMC8856517.
- Uchida Y, Uemura H, Tsuji S, Yamada S, Kouyama JI, Naiki K, Sugawara K, Nakao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Significance of furosemide in patients with cirrhosis treated with or without zinc acetate hydrate supplementation. Hepatol Res. 2022 May;52(5):449-461. doi: 10.1111/hepr.13751. Epub 2022 Feb 21. PubMed PMID: 35113468.
2020年
- Uchida Y, Inao M, Tsuji S, Uemura H, Kouyama JI, Naiki K, Sugawara K, Nakao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis. Hepatol Res. 2020 Dec;50(12):1355-1364. doi: 10.1111/hepr.13566. Epub 2020 Sep 21. PubMed PMID: 32886950.
- Uchida Y, Tsuji S, Uemura H, Kouyama JI, Naiki K, Sugawara K, Nakao M, Inao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis. Hepatol Res. 2020 Nov;50(11):1264-1274. doi: 10.1111/hepr.13564. Epub 2020 Sep 26. PubMed PMID: 32833292.
- Tsuji S, Uchida Y, Uemura H, Kouyama JI, Naiki K, Nakao M, Motoya D, Sugawara K, Nakayama N, Imai Y, Tomiya T, Mochida S. Involvement of portosystemic shunts in impaired improvement of liver function after direct-acting antivirals therapies in cirrhotic patients with hepatitis C virus. Hepatol Res. 2020 Apr;50(4):512-523. doi: 10.1111/hepr.13471. Epub 2020 Jan 13. PubMed PMID: 31837277.
2019年
- Uchida Y, Nakao M, Tsuji S, Uemura H, Kouyama JI, Naiki K, Motoya D, Sugawara K, Nakayama N, Imai Y, Tomiya T, Mochida S. Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate. J Med Virol. 2020 Mar;92(3):329-338. doi: 10.1002/jmv.25644. Epub 2019 Dec 9. PubMed PMID: 31777965. Erratum in: J Med Virol. 2020 Aug;92(8):1370. doi: 10.1002/jmv.25837. Epub 2020 Apr 17. PubMed PMID: 32677098.
- Uchida Y, Kouyama JI, Naiki K, Uemura H, Tsuji S, Sugawara K, Nakao M, Motoya D, Nakayama N, Imai Y, Tomiya T, Mochida S. A Case of Genotype-3b HCV in which Whole-genome was Successfully Analyzed Using Third-Generation Nanopore Sequencing. Hepatol Res. 2019 Sep;49(9):1083-1087. doi: 10.1111/hepr.13339. Epub 2019 Jun 13. PubMed PMID: 30924272.
- Uemura H, Uchida Y, Kouyama JI, Naiki K, Tsuji S, Sugawara K, Nakao M, Motoya D, Nakayama N, Imai Y, Tomiya T, Mochida S. NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir. J Gastroenterol. 2019 May;54(5):459-470. doi: 10.1007/s00535-018-01543-9. Epub 2019 Jan 5. PubMed PMID: 30612205.
2018年
- Uchida Y, Naiki K, Kouyama JI, Sugawara K, Nakao M, Motoya D, Inao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy. PLoS One. 2018 Oct 11;13(10):e0205600. doi: 10.1371/journal.pone.0205600. eCollection 2018. PubMed PMID: 30308053; PubMed Central PMCID: PMC6181393.
- Uchida Y, Nakamura S, Kouyama JI, Naiki K, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Hedskog C, Brainard D, Mo H, Mochida S. Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis. Sci Rep. 2018 Jun 11;8(1):8818. doi: 10.1038/s41598-018-27291-7. PubMed PMID: 29892096; PubMed Central PMCID: PMC5995875.
2017年
- Uemura H, Uchida Y, Kouyama JI, Naiki K, Yamaba S, Fuchigami A, Saito Y, Shiokawa K, Fujii Y, Uchiya H, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy. Hepatol Res. 2018 Mar;48(4):233-243. doi: 10.1111/hepr.12980. Epub 2017 Oct 20. PubMed PMID: 28884930.
- Kurata H, Uchida Y, Kouyama JI, Naiki K, Nakazawa M, Ando S, Nakao M, Motoya D, Sugawara K, Inao M, Imai Y, Nakayama N, Tomiya T, Mochida S. Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals. Hepatol Res. 2018 Feb;48(3):E372-E378. doi: 10.1111/hepr.12977. Epub 2017 Sep 25. PubMed PMID: 28872737.
- Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Imai Y, Nakayama N, Mochida S. "Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatol Res. 2017 Dec;47(13):1397-1407. doi: 10.1111/hepr.12882. Epub 2017 Apr 19. PubMed PMID: 28239934.
2016年
- Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Imai Y, Nakayama N, Mochida S. Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism. Hepatol Res. 2016 Nov;46(12):1234-1246. doi: 10.1111/hepr.12673. Epub 2016 Mar 30. PubMed PMID: 26878268.
2015年
- Uchida Y, Kouyama J, Naiki K, Sugawara K, Ando S, Nakao M, Motoya D, Inao M, Imai Y, Nakayama N, Mochida S. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing. J Gastroenterol. 2016 Mar;51(3):260-70. doi: 10.1007/s00535-015-1106-8. Epub 2015 Aug 6. PubMed PMID: 26245700.
2014年
- Uchida Y, Kouyama J, Naiki K, Mochida S. A novel simple assay system to quantify the percent HCV-RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014 Nov 14;9(11):e112647. doi: 10.1371/journal.pone.0112647. eCollection 2014. PubMed PMID: 25397971; PubMed Central PMCID: PMC4232421.
2013年
- Uchida Y, Kouyama JI, Naiki K, Sugawara K, Inao M, Nakayama N, Mochida S. Novel hepatitis B virus strain developing due to recombination between genotypes H and B strains isolated from a Japanese patient. Hepatol Res. 2014 Oct;44(11):1130-1141. doi: 10.1111/hepr.12238. Epub 2013 Oct 25. PubMed PMID: 24020990.